Pharmacokinetic and pharmacodynamic properties of obinutuzumab. (A) Mean serum concentrations of obinutuzumab over time. (B) B-lymphocyte count over time in all GAUGUIN study participants. Reported lymphocyte counts are preinfusion for each. FU, follow-up; SD, standard deviation; W, week. The 2 patients who were B-cell depleted at screening were included based on prior CLL diagnoses and lymph node progression.